Lifesci Capital Reduces Earnings Estimates for Opus Genetics

Opus Genetics, Inc. (NASDAQ:IRD) – Research analysts at Lifesci Capital reduced their Q2 2026 earnings per share estimates for Opus Genetics in a report released on Friday, May 8th. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings of ($0.17) per share for the quarter, down from their previous forecast of ($0.13). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($0.56) per share. Lifesci Capital also issued estimates for Opus Genetics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.59) EPS.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald assumed coverage on shares of Opus Genetics in a research report on Monday, March 30th. They issued an “overweight” rating and a $15.00 price target for the company. Citigroup began coverage on Opus Genetics in a research report on Tuesday, April 28th. They issued an “outperform” rating on the stock. BTIG Research lifted their price target on shares of Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a research note on Tuesday, April 21st. Finally, Oppenheimer began coverage on shares of Opus Genetics in a research report on Monday, March 16th. They issued an “outperform” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Opus Genetics has a consensus rating of “Moderate Buy” and a consensus price target of $10.30.

Opus Genetics Price Performance

Shares of IRD stock opened at $5.18 on Wednesday. Opus Genetics has a one year low of $0.90 and a one year high of $5.81. The stock has a fifty day moving average price of $4.96 and a 200 day moving average price of $3.29. The stock has a market cap of $369.85 million, a P/E ratio of -6.32 and a beta of 0.62.

Opus Genetics (NASDAQ:IRD) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.59). The firm had revenue of $2.16 million for the quarter. Opus Genetics had a negative net margin of 349.33% and a negative return on equity of 338.88%.

Insider Buying and Selling at Opus Genetics

In related news, President Benjamin R. Yerxa sold 7,470 shares of Opus Genetics stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $5.24, for a total value of $39,142.80. Following the sale, the president owned 711,535 shares of the company’s stock, valued at approximately $3,728,443.40. The trade was a 1.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ashwath Jayagopal sold 7,542 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total value of $39,142.98. Following the completion of the transaction, the insider owned 509,233 shares of the company’s stock, valued at approximately $2,642,919.27. This represents a 1.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 73,395 shares of company stock valued at $382,278. Corporate insiders own 11.70% of the company’s stock.

Institutional Trading of Opus Genetics

A number of hedge funds have recently made changes to their positions in IRD. Balyasny Asset Management L.P. acquired a new position in shares of Opus Genetics during the 4th quarter worth approximately $5,463,000. Millennium Management LLC acquired a new stake in shares of Opus Genetics during the 4th quarter worth about $4,025,000. Nantahala Capital Management LLC boosted its holdings in shares of Opus Genetics by 42.9% during the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after buying an additional 1,435,407 shares during the period. Mink Brook Asset Management LLC grew its stake in Opus Genetics by 34.5% in the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after buying an additional 427,684 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Opus Genetics by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock valued at $2,214,000 after acquiring an additional 349,825 shares during the period. 14.97% of the stock is owned by institutional investors and hedge funds.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.